Several possible studies
Story checked
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 (opens in a new tab)
prnewswire.com · 2026-10-21
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
prnewswire.com · 2026-10-21
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedLakewood-Amedex Biotherapeutics presented research at IDWeek 2026 highlighting Nu-3's broad-spectrum antimicrobial activity and low potential for resistance.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 5Not checkedThe poster says Nu-3 showed broad-spectrum and rapid bactericidal activity against Gram-positive, Gram-negative, and multidrug-resistant bacteria, with bacterial eradication occurring within minutes for tested pathogens, and activity against biofilm organisms.View evidenceHide evidence
As statederadication occurring within minutes; compared with a 600- to 2,000-fold increase for ciprofloxacin
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 5Not checkedSerial-passage testing reportedly showed only a slight increase in MIC values against Staphylococcus aureus and Escherichia coli, compared with a 600- to 2,000-fold increase for ciprofloxacin.View evidenceHide evidence
As statedonly a slight increase in MIC; 600- to 2,000-fold increase for ciprofloxacin
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 5Not checkedNu-3 is being investigated in an ongoing Phase 2a clinical trial in patients with mildly infected diabetic foot ulcers, and topline data are expected in the first quarter of 2027.View evidenceHide evidence
As statedPhase 2a; first quarter of 2027
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 5Not checkedThe company frames Nu-3 as a potential topical treatment for infected diabetic foot ulcers and a possible new treatment option for difficult-to-treat infections.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
In vitro and in vivo characterization of Bisphosphocin Nu-3-a novel broad-spectrum antimicrobial compound with high potency against resistant pathogens.
Antimicrobial Agents and Chemotherapy · 2025 · PubMed, Europe PMC
Figure 4: Bactericidal penetrative effect of CAPE on multispecies biofilm.
Crossref
Cytocompatibility and antibacterial activity of the ethanolic leaf extract of Rhodomyrtus tomentosa on Enterococcus faecalis biofilm.
2026 · Europe PMC
Reinforcement of the bactericidal effect of ciprofloxacin on Pseudomonas aeruginosa biofilm by hyperbaric oxygen treatment
2016 · Crossref
Comparative effects of saline, streptomycin, and ozone nasal irrigation on Staphylococcus aureus-induced experimental rhinosinusitis: microbiological, histopathological, and biofilm analyses.
2026 · Europe PMC